Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The CDC's vaccine advisory committee voted to recommend annual flu vaccines but against flu shots containing the preservative ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

A CDC advisory panel voted 5–1 to recommend only flu vaccines without the preservative thimerosal, a mercury-containing ...

At 21-42 days post-vaccination, the geometric mean haemagglutination inhibition titres were 32% higher for H1N1, 55% for H3N2, and 39% for B strains among recipients of the high-dose vaccine than ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

including A/H1N1, A/H3N2 and the B/Victoria lineages. Moderna said the vaccine's benefit was consistent across different age groups, people with various risk factors and previous vaccination status ...

Apr. 23, 2025 — A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as ...

Among children nationwide who were eligible for flu vaccination and with known vaccine status, 90% of the reported U.S. pediatric flu deaths in the ongoing 2024-2025 season — compared to 82% ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.